Leadership - HiFiBio Therapeutics
About
HiFiBiO Therapeutics is a clinical-stage biotech driving a pipeline of transformative immunotherapies.
Leadership
Fred Dom, MSc
Chief Executive Officer
Fred Dom is one of the original founders and Chief Executive Officer of HiFiBiO Therapeutics. He is a serial entrepreneur with expertise in private capital investment and biotech formation in the Netherlands, France, and US. Fred holds board positions in Calyxia (France), Kapsera (France) and Oncode Accelerator (Dutch public-private initiative with €325 million funding from National Growth Fund), and he is a member of the Advisory Board of Dutch Life Science and Health industry.
Previously, Fred was Chief Executive Officer and co-founder of Saber Bio (created in 2021), which was acquired by a world leading life science tools company in 2024. Before Saber, Fred held CEO and CFO positions at HiFiBiO Therapeutics.
Fred holds a B.Sc. and M.Sc. in economics from the Erasmus University in Rotterdam, the Netherlands.
Helmuth Van Es, PhD
Strategic Advisor
Helmuth van Es is a seasoned biotech entrepreneur and strategic advisor with more than 30 years of experience spanning drug discovery, company building, and corporate strategy. He has co-founded multiple international biotechnology companies, including Galapagos, Citryll, Antabio, Audion Therapeutics, and Effecta Pharma. Dr. van Es brings deep expertise in R&D strategy, business development, fundraising, and executive leadership, with a track record of serving as CEO, CSO, CBO, board member, and advisor across the biotech ecosystem.
He previously co-founded and served as CEO of Citryll, where he advanced a first-in-class antibody program targeting NETosis into the clinic, now in phase 2 studies for 2 indications, and secured significant international financing.
Dr. van Es holds an MSc in Biology/Chemistry and a Ph.D. in Medicine from the University of Amsterdam and completed postdoctoral research at the Albert Einstein College of Medicine, New York and McGill University in Montréal.
Jinping Gan, PhD
Senior VP, Head of R&D
Jinping is the Senior Vice President, Head of Research and Development at HiFiBiO Therapeutics. Jinping has more than 25 years of experience in drug discovery and development. Prior to HiFiBiO, Jinping was at Bristol-Myers Squibb working on preclinical optimization and nonclinical characterization of diverse NCEs in oncology, immunology, CV, and fibrotic diseases, contributing to the development and approval of ixabepilone and apixaban.
Jinping received his B.S. from University of Science & Technology of China and his Ph.D. in Biological Chemistry from MIT.
Roshan Kumar, PhD
Executive Director, Head of Translational Medicine
Roshan Kumar is the Head of Translational Medicine at HiFiBiO Therapeutics. He is a scientist with over 20 years of experience in the study of complex biological systems, focusing on human immunology and immune-mediated disease. His current focus is on translating human immune biology into biomarker-driven insights that inform therapeutic strategy and early clinical development.
Roshan received a B.S. from the California Institute of Technology and Ph.D. in Biochemistry from the Scripps Research Institute.
Melissa Harney
Sr. Director, Head of Clinical Operations & Regulatory Affairs
Melissa Harney is the Head of Clinical Operations & Regulatory Affairs at HiFiBiO Therapeutics, where she leads global clinical execution and regulatory strategy across the company’s Immunology & Inflammation and Immuno-Oncology programs. She brings over 20 years of experience in clinical development, regulatory oversight, and global trial operations within the biotech and pharmaceutical sectors.
Melissa holds a Bachelor of Science degree in Clinical Psychology and an Associate degree in Healthcare Science, and completed professional certification programs through Association of Clinical Research Professionals (ACRP).
Yun-Yueh Lu, PhD
Head of Research, Head of China Operations
Yun-Yueh Lu is the Head of Research, Head of China Operations at HiFiBiO Therapeutics. She currently oversees all aspects of preclinical research activities, along with managing general operational responsibilities in China.
Yun-Yueh holds a Ph.D. in Infection Biology from Basel University in Switzerland.
Timothy Miller, MSc
Executive Director, Head of Business Development
Tim Miller is Head of Business Development at HiFiBiO Therapeutics, where he leads global partnering strategy to advance the company’s biotherapeutic pipeline. He holds a Master’s degree in International Infectious Disease Management and Biosecurity from North Dakota State University.
Alexandre Grassin
Senior VP, Head of Finance
Alexandre Grassin is Senior Vice President, Head of Finance at HiFiBiO Therapeutics. He has over 25 years of international experience across the U.S. and Europe, spanning both private and public companies.
Alex holds a degree in International Management and is based in Boston.